Hosted on MSN10mon
New bowel tumor drug helped cure cancer in 100% of cases
We look forward to evaluating dostarlimab-gxly in certain colorectal cancers in our ongoing AZUR-1 and AZUR-2 registrational studies." GSK said the patients in the study did not experience adverse ...
Medical miracle? Experimental drug wipes out colorectal cancer completely in trial
In what can be termed a never-seen-before medical miracle, a small group of people with colorectal cancer achieved 100% ...
LIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer
Started Two New Clinical Trials, Collaborating with MD Anderson and The Netherlands Cancer Institute for Treatment of Ovarian and Colorectal ...
Nasdaq1mon
LIXTE Biotechnology Teams Up with Lurie Cancer Center to Initiate Clinical Trial of LB-100 and GSK’s Dostarlimab for Ovarian Clear Cell Cancer
Lurie Cancer Center initiates trial combining LIXTE's LB-100 and GSK's Dostarlimab for ovarian clear cell cancer treatment. LIXTE Biotechnology Holdings, Inc. has announced that the Robert H.
Lixte Biotechnology provides update on progress with LB-100
LIXTE Biotechnology (LIXT) provided an update on its recent activities. Recent LIXTE Highlights Include: The first patient dosing in a Phase ...
Yahoo Finance12d
LIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer
Our colorectal trial, supported by F ... in a Phase 1b/2 trial combining LIXTE's LB-100 with GSK's immunotherapy, dostarlimab-gxly, targeting ovarian clear cell carcinoma. Dosing of the first ...